Abbott says it's restarting the production of infant formula at its Sturgis, Mich., plant in a step that could ease a nationwide formula shortage in the coming weeks.
The facility was forced to close in February after a bacterial contamination was found in the company's formula products. Several babies were sickened and two died after consuming formula made at the plant.
The closure intensified ongoing supply shortages of baby formula in the U.S. To help alleviate the scarcity, the Biden administration has been importing formula from abroad in recent weeks.
Abbott's specialty formula EleCare will be available to consumers beginning on or about June 20, the company says. EleCare is formulated for infants with allergies to cow milk.
Abbott, one of the largest of the few formula makers in the U.S., was cleared to restart production the Michigan facility after meeting initial FDA requirements.
"We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America," Abbott said in a statement on Saturday.
"We will ramp production as quickly as we can while meeting all requirements," the company added. "We're committed to safety and quality and will do everything we can to re-earn the trust parents, caregivers and health care providers have placed in us for 130 years."
The Food and Drug Administration has been working "around-the-clock" to alleviate the supply shortages, an agency spokesperson said in a statement to NPR. The FDA expects the resumption of production at the Michigan plant "will mean more and more infant formula is either on the way to or already on store shelves moving forward," the spokesperson added.
